Cancer Vaccine Patent hESCs TLR3 Adjuvant Assigned to INSERM
Summary
USPTO granted patent US12599662B2 to INSERM for a cancer vaccine composition using irradiated human embryonic stem cells combined with a TLR3 adjuvant. The patent covers methods for treating cancers including breast cancer by inducing MHC-I presentation of antigens. The patent includes 16 claims.
What changed
USPTO granted patent US12599662B2 to INSERM (Institut National de la Santé et de la Recherche Médicale) for a method of treating cancers using irradiated hESCs combined with TLR3 adjuvant. The vaccine composition includes an agent inducing MHC-I presentation of antigens and an immunogenic element. The patent specifically covers breast cancer treatment where hESC+TLR3 demonstrated highest tumor volume reduction (p<0.001) versus TLR9 or Quil-A adjuvants.
Affected parties including pharmaceutical manufacturers, biotech companies, and research institutions should monitor this patent for licensing opportunities or freedom-to-operate considerations in the cancer immunotherapy space.
What to do next
- Monitor for updates
Archived snapshot
Apr 15, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Methods and compositions for treating cancers
Grant US12599662B2 Kind: B2 Apr 14, 2026
Assignee
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
Inventors
Frank Griscelli, Ali Turhan, Annelise Bennaceur Griscelli
Abstract
The invention relates to a method for treating cancers. Many cancers harbour sternness signature to de-differentiate into immature progenitors confer to tumor clones the re-expression of genes from fetal development. Inventors have obtained mice per group which received two boosts of vaccine 7 and 14 days with 2×106 irradiated hESCs cells that were mixed with 3 different adjuvants: 500 μg of TLR3, 50 μg of TLR9 agonist or 50 μg/ml of Quil A® Saponin vaccine adjuvant. After 14 days 5×104 4T1 cells were injected into the mammary fat pad of the mice and Valproic acid added in the drinking water at the dose of 4 mg/ml. They have shown that in contrast to the non-vaccinated mice, the mice vaccinated with hESC combined with a TLR3 agonist have generated the highest reduction of breast tumor volume (p<0.001) compared to the use of a TLR9 agonist or to Quil-A® Saponin vaccine adjuvant. Accordingly, the invention relates to a method for treating a subject suffering from a cancer with i) an agent that induces MHC-I presentation of antigens, ii) a vaccine composition containing an immunogenic element and iii) an adjuvant.
CPC Classifications
A61K 39/461 A61K 39/39 A61K 2039/515 A61K 2039/55561 A61K 39/464401 A61K 45/06 A61K 2300/00 A61P 35/00 A61P 35/02 A61P 35/04
Filing Date
2019-08-06
Application No.
17265580
Claims
16
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.